Medicine and Dentistry
Neoplasm
100%
Wilms' Tumor
80%
Chemotherapy
73%
Non Small Cell Lung Cancer
56%
Breast Cancer
55%
Overall Survival
52%
Radiation Therapy
49%
Kidney Tumour
44%
Recurrent Disease
36%
Disease
34%
Positron Emission Tomography
31%
Childhood Cancer
30%
Fluorodeoxyglucose F 18
27%
Surgery
26%
Malignant Neoplasm
25%
Polyethylene Terephthalate
23%
Metastatic Carcinoma
21%
Randomized Controlled Trial
20%
Lymph Node
20%
Hazard Ratio
20%
Obstructive Sleep Apnea
20%
Event Free Survival
20%
Squamous Cell Carcinoma
18%
Arm
18%
Carboplatin
18%
Hyperthermic Intraperitoneal Chemotherapy
18%
Melanoma
17%
Preoperative Chemotherapy
17%
Colorectal Carcinoma
17%
Systemic Therapy
16%
Lung Cancer
15%
Cisplatin
15%
Pediatrics
15%
Adverse Event
15%
Prognostic Factor
14%
Drug Megadose
14%
Penis Carcinoma
14%
Cystectomy
13%
Diagnosis
13%
Carcinomatous Peritonitis
13%
Biopsy Technique
13%
Computer Assisted Tomography
13%
High Dose Chemotherapy
12%
Chemoradiotherapy
12%
Positron Emission Tomography-Computed Tomography
12%
Scintigraphy
12%
Phallus
11%
Sentinel Node
11%
Tongue
11%
Progression Free Survival
10%
Keyphrases
Wilms Tumor
73%
Tumor
66%
Overall Survival
49%
Chemotherapy
47%
Radiotherapy
37%
Renal Tumor
36%
Non-small Cell Lung Cancer (NSCLC)
35%
Confidence Interval
35%
Tumor Research
32%
Dutch
30%
Pediatric Oncology
29%
Netherlands
26%
Carboplatin
25%
Breast Cancer
23%
Preoperative Chemotherapy
23%
Event-free Survival
23%
Breast Cancer Patients
22%
Hazard Ratio
22%
Randomized Trial
22%
Positron Emission Tomography
22%
Phase II Study
22%
Bevacizumab
21%
Colorectal Cancer
20%
Capecitabine
20%
Cisplatin
18%
5-year Survival
18%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
18%
70-gene Signature
17%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
17%
Head-and-neck Cancer
16%
High Risk
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
16%
Penile Carcinoma
16%
Obstructive Sleep Apnea-hypopnea Syndrome (OSAHS)
16%
Progression-free Survival
15%
Randomized Phase III Trial
15%
Primary Tumor
15%
International Society
15%
Metastatic Breast Cancer
15%
Prophylactic Cranial Irradiation
15%
Doxorubicin
14%
Neoadjuvant
14%
Computed Tomography
14%
Erlotinib
14%
Tumor Volume
14%
High Dose
13%
Breast Cancer Risk
13%
Peritoneal Carcinomatosis
13%
Intermediate Risk
13%
High-dose Chemotherapy
13%